The founding scientific team at BioSkryb combines deep experience in the development of highly sensitive and accurate tools for single-cell analysis, with a key focus on the research and clinical needs of new applications that enable improved health management. We are rapidly building the infrastructure to make those tools widely available to the research community and others.
The SkrybAmp system, for the first time, provides the required breadth, specificity, and sensitivity to define cellular heterogeneity at the level of the most basic building blocks of life.
While we realize that the new levels of genome resolution enable advances across the broad spectrum of genotyping applications, and we are providing tools supporting those advances, the team is driven by a paramount mission: to provide medical researchers and clinicians with the ability to elucidate the mechanisms of pathology in the genome.
Powered by primary template-directed genome amplification (PTA) the SkrybAmp system allows the unprecedented variant determination and genome coverage required to define combinations of mutations which interfere with the basis of cellular function. PTA provides best-in-class analysis of DNA in small samples, even a single cell. Applications include basic research in cellular heterogeneity improved genotyping, analysis of minimal residual disease in cancer treatment, exact specification of how our genomes are modified through interactions with our environments, determining side effects of purposeful gene modification such as CRISPR, and many others.